spacer
home > ebr > summer 2004 > panacea in the pipeline - promising drug development efforts offer hope to cancer patients
PUBLICATIONS
European Biopharmaceutical Review

Panacea in the Pipeline - Promising Drug Development Efforts Offer Hope to Cancer Patients

The fight against cancer is one of the most arduously fought battles that the global pharmaceutical industry is engaged in. Cancer therapeutics R&D has evolved over the years in its attempt to find the cure for cancer in its many avatars. We might not know all about cancer and how to conquer it even today, but our knowledge about cancer and the therapeutic interventions is significant, given what it was even as recently as a decade ago. Basic and applied research in oncology has evolved by leaps and bounds, and there are more players with increasingly new approaches and a considerably growing number of pipeline drugs that are trying to tackle some of the biggest killer cancer types. Newer technologies and novel techniques have been deployed by the industry in this pitched battle; emerging and nascent disciplines like biotechnology and nanotechnology hold a lot of promise. This article takes a look at some of these efforts to understand what is in store for millions of hopeful cancer patients across the world.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Rajaram Sankaran, Industry Analyst with Frost & Sullivan's Technical Insights Division

Rajaram Sankaran is an Industry Analyst for Frost and Sullivan's Technical Insights Division, tracking advances in the pharmaceuticals, biotechnology, medical devices and diagnostic imaging industries. He is currently working on a research service entitled 'Nanomedicine - Global Developments and Growth Opportunities'. Previous experience includes assignments for Procter and Gamble, Roche Molecular Diagnostic Systems and two of India's top 10 pharmaceutical companies, Lupin Laboratories and Ranbaxy Laboratories. Rajaram graduated from Nagarjuna University in Physical Sciences and completed postgraduate studies in Management at IIFM, Bhopal.

spacer
Rajaram Sankaran
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) a subsidiary of WuXi AppTec and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

The Process of Informed Consent (written by ACRP)

CenterWatch

Every investigator and clinical research coordinator (CRC) should recognize the importance of obtaining valid and appropriate informed consent as an important protection of the rights and welfare of human subjects. The purpose of this ACRP guidance document is not to provide a literature review or summarize the recommendations of various working groups. Instead, the Association decided it would be helpful to provide short and focused guidance which describes how to best structure the informed consent process in accordance with best practices.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement